Alglucerase for Gaucher’s Disease

Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: in vivo c1earance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 15: 269–278, 1978 Barton NW, Brady R, Dambrosia JM. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1564–1565, 1993 Barton NW, Brady RO, Dambrosia JM, et al. Replacement therapy for inherited enzyme deficiency - macrophage-targeted glucocerebrosidase for Gaucher’s di sease. New England Journal of Medicine 324: 1464–1410, 1991a Barton NW, Brady RO, Murray GJ, et al. Enzyme-replacement therapy for Gaucher’s disease: reply. New England Journal of Medicine 325: 1811, 1991b Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proceedings of the National Academy of Sciences of the United States of America 87: 1913–1916, 1990 Beutler E. Gaucher disease: new molecular approaches to diagnosis and treatment. Science 256: 794–199, 1992 Beutler E, Dale GL, Guinto E, Kuhl W. Enzyme replacement therapy in Gaucher’s disease: preliminary clinical lrial of a new enzyme preparation. Proceedings of the National Academy of Sciences of the United States of America 74: 4620–4623, 1977 Beutler E, Figueroa M, Koziol J. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1567, 1993a Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. British Journal of Haematology, in press, 1993 Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. American Journal of Human Genetics 52: 85–88, 1993b Beutler E, Kay A, Saven A. et al. Enzyme replacement therapy for Gaucher disease. Blood 78: 1183–1189, 1991 Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher’s disease. New England Journal of Medicine 291: 989–993, 1974 Culbertson VL, Rhodes RS, Hill EP, Rhodes PJ. Impact of home infusion therapy on the Colorado Medicaid program budget. American Journal of Hospital Pharmacy 45: 1346–1349, 1988 De Duve C. From cytases to Iysosomes. Federal Proceedings 23: 1045–1049, 1964 Doebber TW, Wu MS, Bugianesi RL, ct al. Enhanced macrophage uptake of synthetieally glycosylated human placental beta-glucocerebrosidase. Journal of Biological Chemistry 257: 2193–2199, 1982 Eto Y, Kawame H, Hasegawa Y, Ohashi T, Ida H, et al. Molecular characteristics in Japanese patients with lipidosis: novel mutations in metachromatic leukodystrophy and Gaucher disease. Molecular and Cellular Biochemistry 119: 179–184, 1993 Fallet S, Sibille A, Mendelson R, Shapiro D, Hermann G, et al. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatric Research 31: 496–502, 1992 Figueroa ML, Rosenbloom BE, Kay AC, et al. A less costly regimen of alglucerase to treat Gaucher’s disease. New England Journal of Medicine 327: 1632–1636, 1992 Forster J, Chambers JP, Peters SP, Lee RE, Glew RH. Acute neuropathic Gaucher disease in a black infant. Journal of Pediatrics 93: 823–824, 1978 Furbish FS, Oliver KL, Zirzow GC, Brady RO, Barranger JA. Interaction of human placental glucocerebrosidase with hepatic lectins. In Barranger and Brady (Eds). Molecular basis of lysosomal storage disorders, pp.219-232, Academic Press Inc., New York, 1984 Garber AM, Clarke AE, Goldman DP, Gluck ME. Federal and private roles in the development and provision of alglucerase therapy for Gaucher disease. US Congress, Office of Technology Assessment, US Government Printing Office, Washington DC, 1992 Hollak CEM, Aerts JMFG, van Oers MHJ. Treatment of Gaucher’s disease. New England Journal of Medicine 328: 1565–1566, 1993 Kay AC, Saven A, Garver P, Thurston DW, Rosenbloom BF, et al. Enzyme replacement therapy in type I Gaucher disease. Transactions of the Association of American Physicians 104: 258–264, 1991 Muguti GI, Nijland A, Gwavava NJT, Nkanza NK. Gaucher’s disease in Zimbabwe. Central African Journal of Medicine 33: 267–269, 1987 Murray GJ, Doebber TW, Shen TY, et al. Targeting of synthetically glycOsylated human placental glucocerebrosidase. Biochemical Medicine 34: 241–246, 1985 Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in thirty three patients treated for 6 to 24 months. Blood 82: 408–416, 1993 Sato Y, Beutler E, Binding, internalization, and degradation of mannose-terminated glucocerebrosidase by macrophages. Journal of Clinical Investigation 91: 1909–1917, 1993 Williams DN, Bosch D, Boots J, Scheider J. Safety, efficacy, and cost savings in an outpatient intravenous anlibiOlic program. Clinical Therapeutics 15: 169–179, 1993 Zimran A, Hollak CEM, Abrahamov A, van Oers MHJ, Kelly M, et al. Home treatment wilh intravenous enzyme replacement therapy for Gaucher disease: an international collaborative stUdy of 33 patients. Blood 82: 1107–1109, 1993